Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates

Summary

In trauma patients, resuscitation treatment of intravascular volume may cause haemodilution including blood cell- and plasma-dilution. After plasma-dilution, fibrinogen is the first factor that decreases to critically low concentrations. Fibrin formed in lowered levels is susceptible to fibrinolysis, a natural forerunner for bleeding. To assess whether a fibrinogen concentrate or a factor XIII (FXIII) concentrate can reverse the impairment of fibrin properties after plasma dilution, different laboratory methods were used to determine thrombin generation and fibrin quantity/quality in a normal plasma sample diluted in vitro. Coagulation and clot lysis by plasmin were triggered with tissue factor and rt-PA, respectively. We found that while the endogenous thrombin potential (ETP) was unaffected after plasma-dilution due to postponement of thrombin decay, levels of fibrinogen and hence fibrin were decreased in dilution degree-dependency. The imbalance between influence of the dilution on thrombin activity and fibrin formation brought unexpected outcomes of fibrin properties: the formed clots favoured the degradation by plasmin but the fibrin networks remained tighter/less permeable. This proteolytic tendency was partly overturned by the fibrinogen concentrate added (total fibrinogen ≥ 2 g/l), and much more affected if used in combination with tranexamic acid (a fibrinolysis inhibitor) at small doses. No reversal effect resulted from the FXIII concentrate added. We conclude that plasma-dilution did reduce the proteolytic resistance of formed clots. The fibrinogen concentrate, better together with small doses of tranexamic acid, may reverse the impairment of fibrin property. The FXIII concentrate is not effective in this regard in our in vitro model using platelet-poor plasma.

Keywords

Plama dilution - coagulopathy - fibrin proteolysis - fibrinogen concentrate - FXIII concentrate - tranexamic acid

• References

• 1 Fuller G, Bouamra O, Woodford M. et al. Recent massive blood transfusion practice in England and Wales: view from a trauma registry. Emerg Med J 2012; 29: 118-123.
• 2 Rourke C, Curry N, Khan S. et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 2012; 10: 1342-1351.
• 3 Levy JH, Szlam F, Tanaka KA. et al. Fibrinogen and haemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114: 261-274.
• 4 Fries D, Martini WZ. Role of fibrinogen in trauma-induced coagulopathy. Br J Anaesth 2010; 105: 116-121.
• 5 Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost 2007; 5 (Suppl. 01) 116-124.
• 6 Rossaint R, Bouillon B, Cerny V. et al. Management of bleeding following major trauma: an updated European guideline. Crit Care 2010; 14: R52
• 7 Hemker HC, Al Dieri R, De Smedt E. et al. Thrombin generation, a function test of haemostatic-thrombotic system. Thromb Haemost 2006; 96: 553-561.
• 8 De Smedt E, Wagenvoord R, Hemker HC. The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution. Thromb Haemost 2009; 101: 165-170.
• 9 Sorensen B, Larsen OH, Rea CJ. et al. Fibrinogen as a hemostatic agent. Semin-Hemost 2012; 38: 268-273.
• 10 Francis CW, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. Blood 1988; 71: 1361-1365.
• 11 Mosesson MW, Siebenlist KR, Hernandez I. et al. Evidence that alpha2-antiplas-min becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation. J Thromb Haemost 2008; 6: 1565-1570.
• 12 Lusher J, Pipe SW, Alexander S. et al. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010; 16: 316-321.
• 13 Ng C, Silliman CC, Pearl G. et al. Treatment of refractory hemorrhage with factor XIII in a patient with hemophilia A with inhibitor. Pediatr Blood Cancer. 2013 Epub ahead of print.
• 14 Nordenhem A, Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand J Clin Lab Invest 1998; 5: 475-483.
• 15 Blombäck B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25: 51-70.
• 16 He S, Cao H, Antovic A. et al. Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. Blood Coagul Fibrinolysis 2005; 16: 61-67.
• 17 He S, Blombäck M, Bark N. et al. The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis. Thromb Haemost 2010; 103: 1076-1084.
• 18 He S, Johnsson H, Zabczyk M. et al. A fibrinogen concentrate Haemocomplet-tan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor. Br J Haematol 2013; 160: 806-816.
• 19 DeyS.. A new rapid air-drying technique for scanning electron microscopy using tetramethylsilane: application to mammalian tissue. Cytobios 1993; 73: 17-23.
• 20 Chitlur M, Lusher J. Standardization of thromboelastography: values and challenges. Semin Thromb Hemost 2010; 36: 707-711.
• 21 Davenport R, Khan S. Management of major trauma haemorrhage: treatment priorities and controversies. Br J Haematol 2011; 155: 537-548.
• 22 Smith C, Al-Nuaimi Y, Wainwright J. et al. The influence of bolus to infusion delays on plasma Tissue Plasminogen Activator levels. Int J Stroke. 2012 Epub ahead of print.
• 23 Collet JP, Park D, Lesty C. et al. Influence of fibrin network conformation and fibrin fibre diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler ThrombVasc Biol 2000; 20: 1354-1361.
• 24 Blombäck B, Bark N. Fibrinopeptides and fibrin gel structure. Biophys Chem 2004; 20: 147-151.
• 25 Veklich Y, Francis CW, White J. et al. Structural studies of fibrinolysis by electron microscopy. Blood 1998; 92: 4721-4729.
• 26 Theusinger OM, Baulig W. et al. In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM). Thromb Hae-most 2010; 104: 385-391.
• 27 Schlimp CJ, Cadamuro J, Solomon C. et al. The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro. Blood Transfus 2012; 13: 1-9.
• 28 Cap AP, Baer DG, Orman JA. et al. Tranexamic acid for trauma patients: a critical review of the literature. J Trauma 2011; 71 1 Suppl S9-14.
• 29 Fiechtner BK, Nuttall GA, Johnson ME. et al. Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesth Analg 2001; 92: 1131-1136.
• 30 Grassin-Delyle S, Tremey B, Abe E. et al. Population pharmacokinetics of tran-examic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Br J Anaesth. 2013 Epub ahead of print.
• 31 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Hae- most 2005; 3: 1894-1904.
• 32 Dirkmann D, Gerlinger K, Gisbertz C. et al. Factor XIII and tranexamic acid but not recombinant Factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood. Anesth Analg 2012; 114: 1182-1188.
• 33 Theusinger O. The inhibiting effect of Factor XIII on hyperfibrinolysis. Editorial Anesth Analg 2012; 114: 1149-1150.